Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Lucentis receives EU approval
The submission was supported by data from two Novartis-funded clinical trials, Restore and Resolve, which showed that Lucentis was superior in providing rapid and sustained visual acuity gain
The submission was supported by data from two Novartis-funded clinical trials, Restore and Resolve, which showed that Lucentis was superior in providing rapid and sustained visual acuity gain
The new product is being developed to satisfy growing demand for the company’s liquid gel cap products, three of which are currently being distributed throughout the nation, Sport
The US Department of Agriculture (USDA) has agreed to guarantee $10m of an $18m mortgage Unilife has now obtained from Metro Bank of Harrisburg to support construction of
Pharmaceutical turnover down 3% to £5,553m and Consumer Healthcare sales up 4% to £1,260m. Excluding pandemic products, group sales were level in the quarter. Excluding pandemic products and
The Advanix biliary stent employs NaviFlex RX delivery system, which offers physicians the flexibility to employ both long-wire and short-wire guidewires during access and stent placement. The Advanix
Pramipexole Dihydrochloride tablets are used to treat signs and symptoms of Parkinson’s disease and for the treatment of Restless Legs Syndrome (RLS). Mylan Pharmaceuticals has received final FDA
Patients receiving Cayston had an adjusted mean actual increase in FEV percent predicted from baseline over six months of 2.05% compared to a 0.66% decrease for patients receiving
As per the terms of the agreement, Depomed received a $5m upfront license fee, and receives reimbursements for its formulation work on the project and is also eligible
Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam susceptible, ß-lactamase
Theravance has posted a net loss of $21.22m for the third quarter 2010, or $0.29 loss per diluted share, compared to a net loss of $22.18m, or $0.35